NPCE - NASDAQ

NeuroPace, Inc.

NPCE·NASDAQ

$15.88

-2.5%

HealthcareMedical - Devices

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$541.41M

EPS-0.6600

P/E Ratio-24.06

Earnings Date08/11/2026

-11.01M

Operating Cash Flow

-39%

3Y-70.0%

5Y-49.0%

10Y-56.0%

-332.00K

Investing Cash Flow

-104%

3Y-101.0%

5Y-97.0%

10Y-109.0%

19.60M

Financing Cash Flow

353%

3Y+3900.0%

5Y-64.0%

10Y-8.0%

NeuroPace, Inc. Cash Conversion Engine

NPCE · NASDAQ

FCF Components

Net Income-21.46M

Depreciation & Amortization1.95M

Stock-Based Compensation11.09M

Change in Working Capital-4.01M

Others1.43M

Capital Expenditures-332.00K

Free Cash Flow-11.34M

Cash Flow Quality Analysis

FCF Conversion Rate

52.8%

Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.

CapEx Intensity

-3.0%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+37.9%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$4.01M

Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

NeuroPace, Inc. Cash Flow Statement

NPCE • NASDAQ

NeuroPace, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-21.5M	-27.1M	-33M	-47.1M	-36.1M	-24.3M	-30M
Depreciation & Amortization	1.9M	1.8M	1.6M	3M	296K	312K	421K
Change in Deferred Taxes	0.0	0.0	0.0	0.0	5.5M	0.0	0.0
Stock-Based Compensation	11.1M	10.3M	9.6M	8.3M	4.3M	1.4M	1.4M
Other Non-Cash Items	1.4M	2.6M	4.6M	3.7M	1.1M	3M	3.1M
Change in Working Capital	-4M	-5.5M	-2.5M	-4.8M	368K	-2.1M	9K
Cash from Operating Activities	-11M	-17.9M	-19.7M	-36.9M	-24.6M	-21.6M	-25M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-332K	-306K	-173K	-603K	-384K	-62K	-468K
Purchase of Investments	(0.0)	(0.0)	(0.0)	(0.0)	-85M	-17M	-18M
Sale/Maturity of Investments	0.0	9.3M	23.2M	24.4M	0.0	6.3M	22.1M
Other Investing Items	0.0	0.0	0.0	0.0	0.0	0.0	4K
Cash from Investing Activities	-332K	(9M)	(23M)	(23.8M)	-85.4M	-10.8M	(3.6M)
FINANCING ACTIVITIES
Net Issuance of Common Stock	22.2M	3.3M	7.9M	0.0	109.1M	0.0	0.0
Net Issuance of Debt	-2.1M	0.0	0.0	0.0	-4.1M	24.5M	21.3M
Share Repurchases	-49.5M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Other Financing Items	-543K	1.1M	239K	490K	-2.5M	-1.1M	42K
Cash from Financing Activities	19.6M	4.3M	8.1M	490K	102.5M	55M	21.4M
CASH FLOW SUMMARY
Net Change in Cash	8.3M	-4.6M	11.5M	-12.6M	-7.4M	22.6M	-38K
Cash at Beginning of Period	13.6M	18.2M	6.7M	19.3M	26.8M	4.1M	4.2M
Cash at End of Period	21.8M	13.6M	18.2M	6.7M	19.3M	26.8M	4.1M
Free Cash Flow	-11.3M	-18.3M	-19.9M	-37.5M	-25M	-21.7M	-25.5M

SEC Filings

NPCE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 21, 2026	June 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 12, 2025	August 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 24, 2025	June 20, 2025	2025	View Filing

Showing 1 to 10 of 76 filings

Related Guides

Blog Categories

Continue your NPCE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.